System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maxime Brunet is an expert in Oncology at Institut Bergonié (France). Maxime Brunet has authored 24 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 6 of them ongoing. SLR score: 235 (community average: 125). How the SLR is computed.

LeadR Profile

Maxime Brunet Institut Bergonié France
235 ScienceLeadR Reputation 235

Unlock

Register Login
Network Map

Oncology

Subspecialties: Immunology - Pulmonology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2019 - 2026
Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 24

Citations

Citations: 747 1st author: 4 Last author: 0 Unique author: 0

Main journals

Cancer Res 4
Ann Oncol 2
Cell Rep Med 2
J Clin Oncol 2
Phys Rev Lett 2

Best Journals

Ann Oncol 2
J Clin Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.
PMID 42242004 — breast neoplasms, neoplasms, breast, therapeutics, plasma		ESMO Open20260
Prognostic significance of tumor fraction in advanced sarcoma: highlighting a novel circulating biomarker.
PMID 41699340 — neoplasms, biomarkers, sarcoma, clinical medicine		Clin Exp Med20260
Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life national setting over a decade.
PMID 41017203 — neoplasms, diagnosis, therapeutics, prognosis, osteosarcoma		Int J Cancer20250
Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures.
PMID 39909044 — cells, neoplasms, carcinoma, non-small-cell lung, tertiary lymphoid structures, immunotherapy, fibroblasts		Cell Rep Med202524
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside.
PMID 39798544 — neoplasms, tertiary lymphoid structures, immunotherapy, immunity, therapeutics		Med20253

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 3
Phase 1/Phase 2 2
N/A 1
Phase 1 1
Phase 2 1

By status:

Recruiting 7
Terminated 1

By type:

Interventional 8

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 2
multicentricup10 6

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 1a 1b Study Investigating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB 43395 Alone or as Part of Combination Therapies in Patients With Metastatic HR HER2 Breast Cancer and Other Advanced Solid Tumors
2023-506888-34-00 — safety, breast neoplasms, neoplasms, breast, therapeutics, pharmacokinetics		Phase 1Recruiting2024
A Study to Learn About the Study Medicine Called PF 07248144 in Combination with Fulvestrant in People with HR positive HER2 negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment
2025-520566-22-00 — fulvestrant, breast neoplasms, neoplasms, hormones, breast, therapeutics		Phase 3Recruiting2025
EstroTEP and circulating biomarkers for ER positive HER2 negative metastatic breast cancer patients
2023-506282-66-00 — aromatase, aromatase inhibitors, breast neoplasms, neoplasms, drug therapy, biomarkers, breast, therapeutics, chemotherapy, women		Phase 3Recruiting2024
ECLECTIC EstroTEP and Circulating Biomarkers for ER positive HER2 negative Metastatic Breast Cancer Patients
NCT06195709 — reading, poly(adp-ribose) polymerase inhibitors, breast neoplasms, radiation oncologists, gonadotropin-releasing hormone, oncologists, pharmaceutical preparations, neoplasms, drug therapy, positron emission tomography computed tomography, biomarkers, neoplasm metastasis, breast, therapeutics, wounds and injuries, chemotherapy, carcinoma		Phase 3Recruiting2024
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early stage TNBC
NCT06078384 — injections, triple negative breast neoplasms, breast neoplasms, lymphocytes, paclitaxel, pharmaceutical preparations, lymphocytes, tumor-infiltrating, neoplasms, drug therapy, solutions, immunotherapy, aged, lymph, breast, therapeutics, chemotherapy, women		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS